Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| epithelial cell | 4 studies | 20% ± 6% | |
| GABAergic neuron | 3 studies | 20% ± 1% | |
| glutamatergic neuron | 3 studies | 29% ± 4% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| brain | 4 studies | 22% ± 5% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| esophagus | 100% | 2174.75 | 1445 / 1445 | 100% | 45.09 | 183 / 183 |
| intestine | 100% | 2877.70 | 966 / 966 | 100% | 51.61 | 527 / 527 |
| stomach | 100% | 2207.94 | 359 / 359 | 100% | 52.98 | 286 / 286 |
| ovary | 100% | 1769.57 | 180 / 180 | 100% | 24.68 | 428 / 430 |
| pancreas | 100% | 2271.77 | 328 / 328 | 99% | 17.01 | 177 / 178 |
| bladder | 100% | 2131.86 | 21 / 21 | 99% | 29.83 | 501 / 504 |
| breast | 100% | 2533.07 | 459 / 459 | 99% | 26.06 | 1107 / 1118 |
| skin | 100% | 3565.83 | 1809 / 1809 | 99% | 26.56 | 467 / 472 |
| lung | 100% | 3280.06 | 578 / 578 | 99% | 26.29 | 1142 / 1155 |
| prostate | 100% | 2934.47 | 245 / 245 | 99% | 19.25 | 495 / 502 |
| uterus | 100% | 2327.68 | 170 / 170 | 98% | 22.28 | 452 / 459 |
| brain | 98% | 1774.25 | 2598 / 2642 | 100% | 19.53 | 702 / 705 |
| thymus | 100% | 2856.00 | 653 / 653 | 98% | 14.80 | 590 / 605 |
| kidney | 100% | 2131.75 | 89 / 89 | 94% | 13.05 | 844 / 901 |
| adrenal gland | 100% | 1928.44 | 258 / 258 | 81% | 8.64 | 187 / 230 |
| liver | 100% | 1305.92 | 226 / 226 | 43% | 4.27 | 174 / 406 |
| adipose | 100% | 2373.08 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 23.35 | 29 / 29 |
| muscle | 100% | 1492.55 | 803 / 803 | 0% | 0 | 0 / 0 |
| spleen | 100% | 3406.98 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 20.62 | 45 / 45 |
| ureter | 0% | 0 | 0 / 0 | 100% | 7.36 | 1 / 1 |
| blood vessel | 100% | 1565.76 | 1333 / 1335 | 0% | 0 | 0 / 0 |
| heart | 98% | 1334.70 | 848 / 861 | 0% | 0 | 0 / 0 |
| peripheral blood | 97% | 2691.08 | 904 / 929 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 96% | 12.50 | 77 / 80 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0005515 | Molecular function | protein binding |
| Gene name | PROSER1 |
| Protein name | Proline and serine-rich protein 1 Proline and serine rich 1 |
| Synonyms | KIAA2032 C13orf23 |
| Description | FUNCTION: Mediates OGT interaction with and O-GlcNAcylation of TET2 to control TET2 stabilization at enhancers and CpG islands (CGIs). . |
| Accessions | ENST00000625998.2 [Q86XN7-2] ENST00000352251.8 [Q86XN7-1] ENST00000418503.1 Q5JS36 Q86XN7 |